drugset / Trial / NCT01369771
The Effects of Preservative-free Prostaglandin Eye Drops in Sign and Symptoms on the Eyes of Patients With Glaucoma
Phase 4
Completed
30 enrolled
FinnMedi Oy
Tampere University · collabThe Laboratory and Pharmacy Public Utility of the Pirkanmaa Hospital District · collab
NaSingle-groupOpen-labelTreatment
Summary
The objective of this study is to investigate corneal confocal microscopic findings, ocular signs and symptoms in patients on treatment with the preserved prostaglandin analogue latanoprost 0.005% eye drops (Xalatan®) and after the switch to preservative-free prostaglandin analog tafluprost 0.0015% eye drops (Taflotan®). Patients who have been using latanoprost as their prior medication (at least 6 months) and who fulfil all the inclusion criteria including the specified ocular symptoms and signs, will switch from latanoprost 0.005% eye drops to the assigned preservative-free tafluprost 0.0015% eye drops for twelve (12) months.
Timeline
- Start
- 2010-08
- Primary completion
- 2012-06
- Completion
- 2012-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tafluprost | Other / unclassified | 0.0015 mg/ml | Topical |
| Subject | Tafluprost | Other / unclassified | 0.3 ml | Topical |